Also in this playlist...
This transcript is automatically generated
Talk about a stock that's booming shares of area pharmaceutical sky -- nearly 200%.
Over the past year up another three and a half percent today and if things go right with three promising cancer drugs in its pipeline.
That perhaps the sky really is the limit for this company let's find out more at a Fox Business exclusive -- -- for Harvey Berger who was the founder chairman.
And CEO -- and what I was writing the -- for this company has -- unit you're trying to save the world you've come up with three special throats right now that are in the pipeline different stages of clinical trial certainly but.
Some of them are really promising the leukemia drug you haven't you've got the soft tissue in this are common drugs in the lung cancer -- but let's get first.
To the one that's called quantitative frank is that -- correct that's right okay you've just got some.
Trials back right investors are dying to know how they want.
But earlier this week -- the and initial preliminary results of the pivotal trial the trial that we -- use for registration of the drug with regulatory agencies around the world.
Were published online so we can talk about them today.
Content and although it's early look at the data it's really only based -- about three months of follow up and three months of treatment with an active.
But even in that -- in that early look.
And we now have close to half of the patients in the chronic form of the disease.
That's the long term form leukemia we're talking about -- chronic -- -- leukemia.
Having responded and these are patients who have failed other drugs who really have few if any options available.
And then even the most advanced patients who have survival may be of 345.
Months we've got.
The very high response rate there are also severe we're doing good and helping those patients as well so -- the board's.
Very -- -- response what is the next step for approval doctor.
So this trial.
The results will be presented at the MP -- blood cancer research meeting in December will continue to follow the patients.
And we expect to file for approval with the worldwide regulatory agencies middle the next year how many patients were in the study.
Sort of around the world -- -- -- will have about 50550.
Patients total from all the trials when we file.
For approval -- -- -- it really tears at your heart strings tugs at them when you think about people who it's their last hope to even be part of the trial in his people -- to be part of these trials but that was.
You know that's exactly what happened in the in the trials called the pace trial on we were initially only in inner about 320 patients around the world.
And we couldn't stop and Romans we ended up and rolling about 450.
Patients so a third more in about half the time.
Because of demand from patients wanted to do it.
Thank -- you've got these soft tissue of the bone tumor that that's sarcoma drunk right that's number two what's happening with -- one.
Well there we have a partner Merck the large pharmaceutical company Merck filed for approval.
-- for -- -- missing bone and soft tissue sarcoma as those of the cancers that affect the -- tissues and organs that hold the body to gather.
They filed for approval in the US and Europe and we hope to have that drug available for patients -- here.
These things are not cheap and to develop them takes years in human capital not just actual money.
Does the Health Care Reform bill.
Does that discourage you and encourage you or makes no difference when it comes to use and we're going to go out on a -- spend the money and look for that the solutions to these problems.
-- -- it doesn't stop us it may affect some investors and looking at the relative risks of investing in the Biotech and pharma industry.
But having said that we've been at this for years we are committed to developing these three drugs as well as other drugs.
And Health Care Reform ultimately is not an impediment.
Because we what we want to have drugs that make a difference flights of mean I I think we have a real chance the first two drugs we have compelling clinical data.
The third drug are lung cancer drugs looking very encouraging as we've moved in into the clinic.
But any one of these three but especially -- that have our drug for chronic leukemia.
That would completely transform the company and really position us -- to build further.
We are following the story.
And the ticker symbol AAR IA again the stock up about a 178%.
We should mention 14% of the -- -- shorted there's some people who don't believe in you but that's classic with a smaller departments classic the good luck -- you.
We hope for the sake of patients out there that -- worked so it's it's great and and I'm sure your buddies at Yale medical school of very proud of -- Thank you -- doctor Harvey Berger -- founder chairman and --
Filter by section